PT3821912T - Terapia do gene rpgr para retinite pigmentosa - Google Patents

Terapia do gene rpgr para retinite pigmentosa

Info

Publication number
PT3821912T
PT3821912T PT201992088T PT20199208T PT3821912T PT 3821912 T PT3821912 T PT 3821912T PT 201992088 T PT201992088 T PT 201992088T PT 20199208 T PT20199208 T PT 20199208T PT 3821912 T PT3821912 T PT 3821912T
Authority
PT
Portugal
Prior art keywords
gene therapy
retinitis pigmentosa
rpgr gene
rpgr
pigmentosa
Prior art date
Application number
PT201992088T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Massachusetts Eye & Ear Infirmary
The Government Of The Us Secretary Department Of Health And Human Services
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary, The Government Of The Us Secretary Department Of Health And Human Services, Ucl Business Ltd filed Critical Massachusetts Eye & Ear Infirmary
Publication of PT3821912T publication Critical patent/PT3821912T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
PT201992088T 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa PT3821912T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028638P 2014-07-24 2014-07-24

Publications (1)

Publication Number Publication Date
PT3821912T true PT3821912T (pt) 2024-08-01

Family

ID=55163577

Family Applications (2)

Application Number Title Priority Date Filing Date
PT201992088T PT3821912T (pt) 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa
PT158253831T PT3191139T (pt) 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT158253831T PT3191139T (pt) 2014-07-24 2015-07-17 Terapia do gene rpgr para retinite pigmentosa

Country Status (18)

Country Link
US (2) US10314924B2 (enExample)
EP (2) EP3821912B1 (enExample)
JP (3) JP6654760B2 (enExample)
CN (1) CN107206105A (enExample)
CA (1) CA2991750C (enExample)
CY (1) CY1123793T1 (enExample)
DK (2) DK3191139T3 (enExample)
ES (2) ES2834402T3 (enExample)
FI (1) FI3821912T3 (enExample)
HR (2) HRP20241154T1 (enExample)
HU (2) HUE068183T2 (enExample)
LT (2) LT3191139T (enExample)
PL (2) PL3191139T3 (enExample)
PT (2) PT3821912T (enExample)
RS (2) RS65909B1 (enExample)
SI (2) SI3191139T1 (enExample)
SM (2) SMT202400309T1 (enExample)
WO (1) WO2016014353A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014353A1 (en) * 2014-07-24 2016-01-28 Massachusetts Eye & Ear Infirmary Rpgr gene therapy for retinitis pigmentosa
US20190054117A1 (en) * 2014-12-19 2019-02-21 Novartis Ag Dimerization switches and uses thereof
AU2016228751B2 (en) 2015-03-11 2022-01-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
GB201704192D0 (en) 2017-03-16 2017-05-03 Nightstarx Ltd Treatment of Retinitis Pigmentosa
KR102763312B1 (ko) * 2017-10-20 2025-02-07 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
MY204271A (en) 2017-11-15 2024-08-20 Ucl Business Ltd Viral vectors comprising rdh12 coding regions and methods of treating retinal dystrophies
CA3174781A1 (en) 2020-03-11 2021-09-16 Massachusetts Eye And Ear Infirmary Gene therapy for nmnat1-associated retinal degeneration
CN120350069A (zh) * 2024-01-12 2025-07-22 北京中因科技有限公司 视网膜色素变性动物模型及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
AU6131086A (en) 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
DE3852823T2 (de) 1987-09-11 1995-05-24 Hughes Howard Med Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
EP0400047B1 (en) 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
EP0556345B2 (en) 1990-10-31 2005-10-12 Cell Genesys, Inc. Retroviral vectors useful for gene therapy
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
AU2044901A (en) * 1999-11-24 2001-06-04 Cornell Research Foundation Inc. Inherited retinal diseases at the canine rp3 locus: linkage, marker- and mutation-based tests
GB0008801D0 (en) * 2000-04-10 2000-05-31 Medical Res Council Sequences
CN102925445A (zh) * 2011-08-08 2013-02-13 刘军 一种获得rpgr 基因新的转录剪切形式的方法
EP2872183B1 (en) * 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
GB201412011D0 (en) * 2014-07-04 2014-08-20 Ucl Business Plc Treatments
WO2016014353A1 (en) * 2014-07-24 2016-01-28 Massachusetts Eye & Ear Infirmary Rpgr gene therapy for retinitis pigmentosa

Also Published As

Publication number Publication date
US10314924B2 (en) 2019-06-11
EP3821912A1 (en) 2021-05-19
CA2991750C (en) 2023-02-14
RS65909B1 (sr) 2024-10-31
RS61307B1 (sr) 2021-02-26
US11045558B2 (en) 2021-06-29
CY1123793T1 (el) 2022-05-27
PT3191139T (pt) 2020-11-05
US20170216454A1 (en) 2017-08-03
JP2022009333A (ja) 2022-01-14
HRP20241154T1 (hr) 2024-11-22
DK3821912T3 (da) 2024-08-05
HRP20202023T1 (hr) 2021-03-05
HUE052781T2 (hu) 2021-05-28
ES2987090T3 (es) 2024-11-13
FI3821912T3 (fi) 2024-08-05
EP3191139B1 (en) 2020-10-07
CA2991750A1 (en) 2016-01-28
LT3821912T (lt) 2024-09-25
SMT202000715T1 (it) 2021-01-05
PL3191139T3 (pl) 2021-07-05
CN107206105A (zh) 2017-09-26
SI3191139T1 (sl) 2021-03-31
SMT202400309T1 (it) 2024-11-15
SI3821912T1 (sl) 2024-10-30
WO2016014353A1 (en) 2016-01-28
EP3821912B1 (en) 2024-06-12
JP7198329B2 (ja) 2022-12-28
ES2834402T3 (es) 2021-06-17
EP3191139A4 (en) 2018-01-10
JP2020073536A (ja) 2020-05-14
PL3821912T3 (pl) 2024-10-28
LT3191139T (lt) 2021-01-25
JP6654760B2 (ja) 2020-02-26
US20200215203A1 (en) 2020-07-09
DK3191139T3 (da) 2020-11-16
EP3191139A1 (en) 2017-07-19
JP2017523239A (ja) 2017-08-17
JP6966532B2 (ja) 2021-11-17
HUE068183T2 (hu) 2024-12-28

Similar Documents

Publication Publication Date Title
IL284741B (en) Gene therapy for retinitis pigmentosa
ZA201802462B (en) Gene therapy
GB201420139D0 (en) Factor IX gene therapy
GB201407322D0 (en) Gene therapy
DK3191139T3 (da) RPGR-genterapi til retinitis pigmentosa
PT3612237T (pt) Terapia genética
GB201513151D0 (en) Functional gene replacement therapy
GB201616821D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
GB201410595D0 (en) Factor IX gene therapy
SG10201912076UA (en) Gene therapy composition